Table 2. Anti-spore antibody responses: titre comparisons of vaccinated and unvaccinated groups.
Week | Group compared with PBS controls* | Highest significant dilution† | |
WT Ames plate | ΔbclA Ames plate | ||
4 | PA alone | <50‡ | <50‡ |
PA+BclA+ExsF combined (3) | 3200 | 3200 | |
PA (1), BclA+ExsF separately (2) | <50‡ | <50‡ | |
8 | PA alone | <50‡ | <50‡ |
PA+BclA+ExsF combined (3) | 3 200 | ≥204 800 | |
PA (1), BclA+ExsF separately (2) | 200 | 800 | |
12 | PA alone | <50‡ | <50‡ |
PA+BclA+ExsF combined (3) | ≥204 800§ | ≥204 800 | |
PA (1), BclA+ExsF separately (2) | 3200 | 51 200 |
The number of total vaccine doses over the course of the entire study is shown in parentheses. Vaccinations were administered on day 0, week 4 and week 8. All vaccinations included AL. For example, the third group in each set of three received one PA dose (25 mg) on day 0 and one PA+spore antigen dose (25 µg) on week 4 and a second on week 8.
Highest dilution with A405 significantly elevated (P<0.05) compared with the PBS control (reciprocal dilution).
P>0.05 at lowest dilution tested (1 : 50).
P<0.05 at highest dilution tested (1 : 204 800).